Conference Coverage

Outcomes-based measurement of TAVR program quality goes live


 

REPORTING FROM ACC 20


“Transparency and outcomes should drive how TAVR is delivered,” commented Ashish Pershad, MD, an interventional cardiologist at Banner-University Medicine Heart Institute in Phoenix who estimated that he performs about 150 TAVR procedures annually. “This is a step forward. I’ve been waiting for this for a long time. Until now, volume has been used as a surrogate outcome, but we know it’s not accurate. I’m confident that this model is a good starting point.” But Dr. Pershad also had concern that this new approach “can lend itself to some degree of gaming,” like a bleeding event getting classified as minor when it was really major, or outlier patients getting dropped from reports.

Dr. Ashish Pershad, interventional cardiologist, Banner-University Medicine Heart Institute

Dr. Ashish Pershad

The temptation to cut corners may be higher for TAVR than it’s been for the cardiac-disease metrics that already get publicly reported, like bypass surgery and myocardial infarction management, because of TAVR’s higher cost and higher profile, Dr. Pershad said. Existing measures “have not been as linked to financial disincentive as TAVR might be” because TAVR reimbursements can run as high as $50,000 per case. “The stakes with TAVR are higher,” he said.

Ultimately, the reliable examination of TAVR outcomes that this new metric allows may lead to a shake-up of TAVR programs, Dr. Pershad predicted. “This is clearly a step toward closing down some programs that [consistently] underperform.”

The STS/ACC TVT Registry receives no commercial funding. Dr. Desai has been a consultant to, speaker on behalf of, and received research funding from Gore, and he has also spoken on behalf of Cook, Medtronic, and Terumo Aortic. Dr. Cleveland, Dr. Mack, and Dr. Pershad had no disclosures.

Pages

Recommended Reading

Transradial access gains converts among U.S. interventional neurologists
MDedge Cardiology
AUGUSTUS: Apixaban surpassed warfarin despite prior stroke or thromboembolism
MDedge Cardiology
Anticoagulants may have advantage over aspirin for low-risk TAVR
MDedge Cardiology
Novel mitral valve device shows encouraging mortality data
MDedge Cardiology
TAVR device orientation may reduce coronary overlap
MDedge Cardiology
Benefit of ultrathin over thin stent still growing at 3 years
MDedge Cardiology
TAVR for low-risk bicuspid aortic stenosis appears safe, effective
MDedge Cardiology
Conscious sedation during TAVR best for most patients
MDedge Cardiology
TAILOR-PCI: Clopidogrel genotyping trial narrowly misses endpoint
MDedge Cardiology
UK TAVI: Similar outcomes to surgery in real world
MDedge Cardiology